Skip to main content
Clinical Trials/NCT01819740
NCT01819740
Unknown
N/A

Analysis of a New Biomarker for Prostate Cancer Diagnosis

Corporacion Parc Tauli1 site in 1 country28 target enrollmentApril 2013

Overview

Phase
N/A
Intervention
Not specified
Conditions
Patients With Suspected Prostate Cancer
Sponsor
Corporacion Parc Tauli
Enrollment
28
Locations
1
Primary Endpoint
substance "HEM" concentration in seminal plasma (mEq/L measured by spectro-photometry
Last Updated
13 years ago

Overview

Brief Summary

The aim of our study is to determine if the levels of the "HEM" substance in seminal plasma are associated with the presence of prostate cancer in transrectal prostate biopsy.

Registry
clinicaltrials.gov
Start Date
April 2013
End Date
April 2013
Last Updated
13 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
Corporacion Parc Tauli
Responsible Party
Principal Investigator
Principal Investigator

MIRIAM BARRIO MUÑOZ

UROLOGY RESIDENT

Hospital de Sabadell

Eligibility Criteria

Inclusion Criteria

  • Clinical or laboratory suspected of prostate cancer

Exclusion Criteria

  • Inability to ejaculate

Outcomes

Primary Outcomes

substance "HEM" concentration in seminal plasma (mEq/L measured by spectro-photometry

Time Frame: 1 hour

Study Sites (1)

Loading locations...

Similar Trials